Since the beginning of 2011, Merck Serono S.A. has done at least eight deals to either in-license or generate candidates in autoimmune, inflammation, cancer and neurodegenerative diseases for its pipeline. During 2007-10, the pharma had done four or five deals a year. Source: BCIQ: BioCentury Online Intelligence


Deal description (prod status at time of deal)

Financial terms


Threshold Pharmaceuticals Inc. (NASDAQ:THLD)

Co-develop and commercialize TH-302, a hypoxia-activated cytotoxic2-nitroimidazole prodrug of the DNA alkylator bromoisophosphoramide mustard (Br-IPM); in Ph III to treat soft tissue sarcoma (STS) and Ph II for advanced pancreatic cancer

$25M up front; up to $525M in milestones; tiered, double-digit royalties; Threshold has option to co-commercialize in U.S. and receive up to 50% of profits